China Sky One Medical, Inc. Obtains Production Approval for Two...( HARBIN China Oct. 30 /Xinhua-- Ch...),Health

HARBIN, China, Oct. 30 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it recently obtained production approval from the State Food and Drug Administration (SFDA) in China for two of its newly developed drugs.

Sodium ferulate by injection is intended for the treatment of cardiovascular disease. It works by inhibiting the gathering of hematoblasts and stretches blood vessels in order to protect cardiac muscles. Doxofylline by injection is intended for the treatment of asthma and bronchitis. It works on bronchia and relaxes bronchial smooth muscle in order to restrain asthma.

"We are very excited about our two new drugs and estimate that revenue from sodium ferulate will reach USD $1 million, and revenue from doxofylline will reach USD $500,000 once production starts in the beginning of 2009," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We are confident that our advanced R&D capabilities will continue to help us expand our market share."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more informati
'/>"/>